EPIRUS Biopharmaceuticals to Release Fourth Quarter and Fiscal Year 2015 Financial Results and Provide Business Update

EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play biosimilar company focused on the development and commercialization of biosimilar monoclonal antibodies (mAbs), today announced it will release its fourth quarter and fiscal year 2015 financial results on Tuesday, March 15, 2016.  In conjunction with the release, the Company has scheduled a conference call and webcast on Tuesday, March 15, 2016 at 8:00 a.m. ET to discuss the financial results and provide a business update.

Conference Call InformationWhen: Tuesday, March 15, 2016, 8:00 a.m. ETDial-in: 1-855-638-3957 (United States) or 1-224-633-1318 (International)Conference ID: 58250825Webcast: http://ir.epirusbiopharma.com/events.cfmPlease join the conference call at least 10 minutes early to register. The webcast will be archived on EPIRUS' website for a period of three months.

About EPIRUS BiopharmaceuticalsEPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a pure-play biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS' goal is to improve global patient access to important, cost-effective medicines. The company’s current pipeline of biosimilar product candidates includes: BOW015 (infliximab, reference biologic Remicade®), currently marketed outside the U.S. and in an ongoing global Phase 3 study for registration in Europe and North America; BOW050 (adalimumab, reference biologic Humira®); BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090 (ustekinumab, reference biologic STELARA®); and BOW100 (golimumab, reference biologic SIMPONI®)i. The reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has established multiple partnerships to support its regulatory and commercialization efforts in global markets.

i. Remicade is a registered trademark of Johnson and Johnson; Humira is a registered trademark of AbbVie; Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group; Stelara is owned and marketed by Centocor Ortho Biotech Inc, a wholly owned subsidiary of Johnson and Johnson; Simponi is marketed by Janssen Biotech Inc; Soliris is a registered trademark of Alexion Pharmaceuticals, Inc.

Contact Information

For investor inquiries:
Marek Ciszewski, J.D., EPIRUS Biopharmaceuticals
[phone]
[e-mail]

For media inquiries:
Hope Buggey, FleishmanHillard 
[phone]  
[e-mail]